Investors Are Hooked On Flipping Pharmaceuticals

Published: Nov 02, 2016

Dealmakers have always flipped companies. Lately, they’ve been flipping something else: aging pharmaceuticals.

Take Actimmune, developed by Genentech Inc. decades ago. By 2012, sales were fizzling. Then rights to the immune-disorder treatment were acquired by a company backed by private equity. The price climbed, 434 percent in two years, and Actimmune was a hot property. Horizon Pharma Plc snapped it up.

Back to news